Related Experiment Videos
Paget's sarcoma: a historical and outcome review
Henry J Mankin1, Francis J Hornicek
1Orthopaedic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. hmankin@partners.org
Clinical Orthopaedics and Related Research
|September 1, 2005
Summary
Paget's sarcoma, a rare bone cancer in the elderly, shows persistently poor survival rates. Despite advances in cancer treatment, outcomes for Paget's sarcoma have not improved significantly over decades.
Area of Science:
- Orthopedic Oncology
- Pathology
- Bone Sarcomas
Background:
- Paget's sarcoma is a rare, highly malignant bone cancer.
- It primarily affects elderly individuals with extensive Paget's disease.
- Common sites include the pelvis, femur, humerus, and calvarium.
Observation:
- A study reviewed 40 Paget's sarcoma cases from two distinct periods (1942-1967 and 1972-2001).
- 35% of tumors were Musculoskeletal Tumor Society Stage III.
- Outcome data were available for 35 patients.
Findings:
- Survival rate was 14% at approximately 2.5 years.
- No significant difference in survival was observed between the two treatment periods.
- This indicates a lack of therapeutic progress for Paget's sarcoma.
Implications:
- The findings highlight the critical need for improved treatment strategies for Paget's sarcoma.
- Further research is essential to enhance patient survival rates.
- This contrasts sharply with advancements seen in standard osteosarcoma treatment.